Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you order an OncoType DX test on a <50 year old woman with T2 N1mi HR+ HER2- breast cancer?
Answer from: Medical Oncologist at Community Practice
Yes. The patient will need chemotherapy as per RxPonder Trial.
Comments
Medical Oncologist at Hollywood Private Hospital
Is this correct? The protocol of RxPonder states-&...
Medical Oncologist at Los Angeles VA Medical Center
For micrometastases and how to interpret, please s...
7816
7819
Sign In
or
Register
to read more
11847
Related Questions
Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?
How would you approach treatment for a postmenopausal patient who was treated more than 5 years ago with AC-T for TNBC, and who now presents with ipsilateral, locally advanced, node-positive TNBC, but has severe residual neuropathy from prior taxane exposure?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
How to treat a patient with bilateral breast cancer, HER2 positive on one side and HER2 negative on the contralateral side, particularly in regards to adjuvant CDK4/6 inhibitors vs Neratinib?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
How do you approach the RxPonder data in premenopausal women with ER/PR+, HER2 negative, pN1, many of whom now qualify for CDK 4/6 inhibitors in adjuvant setting besides endocrine therapy (+/- OFS) if the RS 0-13 and 14-25?
Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
Is this correct? The protocol of RxPonder states-&...
For micrometastases and how to interpret, please s...